BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30268473)

  • 1. Probable hereditary familial overlap syndrome with multiple synchronous lung tumors.
    Cardona AF; Zatarain-Barrón ZL; Rubio C; Martínez S; Ruiz-Patiño A; Ricaurte L; Serna A; Barrios R; Garzón JC; Navarrete C; Balaguera A; Corrales L; Rojas L; Arrieta O
    Lung Cancer; 2018 Oct; 124():279-282. PubMed ID: 30268473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.
    Jia Y; Ali SM; Saad S; Chan CA; Miller VA; Halmos B
    Cancer Biol Ther; 2014 Aug; 15(8):970-4. PubMed ID: 24835218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
    Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
    Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
    Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
    Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-Generation Sequencing: A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases.
    Patel SB; Kadi W; Walts AE; Marchevsky AM; Pao A; Aguiluz A; Mudalige T; Liu Z; Deng N; Lopategui J
    J Mol Diagn; 2017 Nov; 19(6):870-880. PubMed ID: 28866070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EFGR-mutant lung adenocarcinoma and Li-Fraumeni syndrome: report of two cases and review of the literature.
    Ricordel C; Labalette-Tiercin M; Lespagnol A; Kerjouan M; Dugast C; Mosser J; Desrues B; Léna H
    Lung Cancer; 2015 Jan; 87(1):80-4. PubMed ID: 25433984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
    Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
    Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.
    Pelosi G; Pellegrinelli A; Fabbri A; Tamborini E; Perrone F; Settanni G; Busico A; Picciani B; Testi MA; Militti L; Maisonneuve P; Valeri B; Sonzogni A; Proto C; Garassino M; De Braud F; Pastorino U
    Virchows Arch; 2016 Jun; 468(6):651-62. PubMed ID: 27056568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma.
    Belchis DA; Tseng LH; Gniadek T; Haley L; Lokhandwala P; Illei P; Gocke CD; Forde P; Brahmer J; Askin FB; Eshleman JR; Lin MT
    Oncotarget; 2016 Jul; 7(29):45237-45248. PubMed ID: 27304188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
    Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
    Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
    Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.
    Bonanno L; Calabrese F; Nardo G; Calistri D; Tebaldi M; Tedaldi G; Polo V; Vuljan S; Favaretto A; Conte P; Amadori A; Rea F; Indraccolo S
    Lung Cancer; 2016 Jun; 96():52-5. PubMed ID: 27133750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
    Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
    Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target-directed therapy.
    Kim HK; Lee HY; Choi YL; Choi SJ; Choi H; Lee J; Han J; Ahn MJ; Lee KS; Kim J
    Anticancer Res; 2014 Feb; 34(2):707-14. PubMed ID: 24511003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.
    Chevrier S; Arnould L; Ghiringhelli F; Coudert B; Fumoleau P; Boidot R
    Int J Oncol; 2014 Sep; 45(3):1167-74. PubMed ID: 24990411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.
    Reynolds JP; Zhou Y; Jakubowski MA; Wang Z; Brainard JA; Klein RD; Farver CF; Almeida FA; Cheng YW
    Cancer Cytopathol; 2017 Mar; 125(3):178-187. PubMed ID: 28085233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.